Author

S. Kaufman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Ashkenazi· 1 shared A. Gogineni· 1 shared A. H. Kroemer· 1 shared A. Heidersbach· 1 shared A. Khanna· 1 shared A. Le Thomas· 1 shared B. Haley· 1 shared B. Spishock· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ashkenazi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients

C. Ashokkumar, V. Rohan, A. H. Kroemer, S. Rao, G. Mazariegos, B. W. Higgs, S. Nadig, J. Almeda, H. Dhani, K. Khan, N. Yazigi, U. Ekong, S. Kaufman, M. M. Betancourt-Garcia, K. Mukund, , R. Sindhi

This study evaluates T-cell and antibody immunity to SARS-CoV-2 in transplant recipients, finding impaired responses and increased CMV co-infection risk post-infection.

bioRxiv · May 3, 2021 · PreprintImmunology

Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations

M. Hendy, S. Kaufman, M. Ponga

The paper examines how SARS-CoV-2 mutations affect antibody binding and escape, finding that certain mutations enhance ACE2 binding while others reduce antibody effectiveness depending on antibody class.

bioRxiv · Mar 4, 2021 · PreprintBiophysics

Disruption of IRE1α through its Kinase Domain Attenuates Multiple Myeloma

J. M. Harnoss, A. Le Thomas, S. A. Marsters, D. A. Lawrence, M. Lu, Y.-C. A. Chen, J. Qing, K. Totpal, D. Kan, E. Segal, H. Ackerly Wallweber, W. Wang, K. Clark, S. Kaufman, M. Beresini, , A. Ashkenazi

This study shows that disrupting IRE1α's kinase domain reduces multiple myeloma tumor growth and enhances treatment efficacy, suggesting it as a therapeutic target.

bioRxiv · Dec 14, 2018 · PreprintCancer Biology